Polymorphism and expression of macrophage migration inhibitory factor does not contribute to glucocorticoid resistance in idiopathic thrombocytopenic purpura

Author： Lao Wansheng   Xiang Yang   Fang Meiyun   Yang Xifei  

Publisher： Govi-Verlag

ISSN： 0031-7144

Source： Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol.68, Iss.10, 2013-10, pp. : 846-849

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Macrophage migration inhibitory factor

By Lolis Elias   Bucala Richard  

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 2, 2003-04 ,pp. : 153-164

Informa Healthcare

Access to resources Recommend Favorite

Macrophage Migration Inhibitory Factor and the Discovery of Tautomerase Inhibitors

By  

Current Pharmaceutical Design, Vol. 8, Iss. 14, 2002-06 ,pp. : 1297-1317

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Macrophage Migration Inhibitory Factor in Critical Illness

By  

Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 14, 2014-12 ,pp. : 1116-1124

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic opportunities for antagonism of macrophage migration inhibitory factor

By Morand Eric F   Leech Michelle   Iskander Magdy N  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 8, 2003-08 ,pp. : 1189-1212

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for idiopathic thrombocytopenic purpura in adults

By Li Xiaofang   Hou Ming  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 2, 2008-06 ,pp. : 237-254

Informa Healthcare

Access to resources Recommend Favorite